This Peninsula biotech foresaw deals worth $3 billion. Now it's lining up a $57 million merger
December 05, 2018 at 16:32 PM EST
OncoMed's clinical trial failures prevented the Redwood City company from achieving the financial promise of deals with Celgene, Bayer and GlaxoSmithKline. Now a London company is reverse merging with it to get its NASDAQ listing and Peninsula facility.
